THERAPY AND CLINICAL TRIALS: Edited by Erik S.G. Stroes and Gerald F. WattsCan atherosclerosis be cured?Wilkins, John T.a; Gidding, Samuel S.b; Robinson, Jennifer G.cAuthor Information aDepartments of Medicine (Cardiology) and Preventive Medicine, Northwestern University Feinberg School of Medicine Chicago, IL bFH Foundation Pasadena, California cDepartments of Epidemiology & Medicine, Prevention Intervention Center, Iowa City, Iowa, USA Correspondence to Jennifer G. Robinson, MD, MPH, Director, Departments of Epidemiology & Medicine, Prevention Intervention Center, 145 N Riverside Dr S455 CPHB, Iowa City, IA 52242, USA. Tel: +1 319 384 1563/+1 319 384 4010; fax: +1 319 384 4155; e-mail: [email protected] Current Opinion in Lipidology: December 2019 - Volume 30 - Issue 6 - p 477-484 doi: 10.1097/MOL.0000000000000644 Buy Metrics Abstract Purpose of review Determine if evidence supports interventions to prevent development of atherosclerosis and atherosclerotic cardiovascular disease (ASCVD) events and death. Recent findings An extensive body of evidence supports the fundamental causal role of apolipoprotein B lipoproteins in the development of atherosclerosis. Recent epidemiologic studies have shown that LDL-cholesterol (LDL-C) and non-HDL-cholesterol levels in early adults are associated with accelerated subclinical atherosclerosis and an excess of atherosclerotic cardiovascular events later in life. Animal and human data have shown that intensive LDL-C lowering can regress earlier stages of atherosclerosis. Summary The next research priority is evaluating the impact of lowering LDL-C earlier in life to regress early atherosclerosis, followed by trials to demonstrate this approach will eradicate later-life ASCVD events and death. This approach of curing atherosclerosis will likely be the most effective strategy for reducing the huge global burden of atherosclerosis. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.